FDA Regulation of Cannabis-Derived Products
Understanding FDA authority, approved cannabinoid drugs, and the gap between law and enforcement.
This article is general information, not legal advice. Laws change; check current rules with official sources or a lawyer.
The FDA has clear legal authority over cannabis-derived products under the Federal Food, Drug, and Cosmetic Act, but enforcement is selective. Only one cannabis-derived drug (Epidiolex) is FDA-approved. CBD cannot legally be sold as a supplement or food ingredient — yet the FDA has not systematically removed it from shelves. This gap between law and practice is why 'FDA-compliant CBD' labels are marketing language, not regulatory approval.
FDA Authority and the 2018 Farm Bill
The FDA regulates cannabis-derived products under the Federal Food, Drug, and Cosmetic Act whenever they are marketed as drugs, foods, dietary supplements, cosmetics, or for animal use Strong evidence[1]. The Drug Enforcement Administration (DEA) separately controls drug scheduling under the Controlled Substances Act.
The 2018 Farm Bill removed hemp—defined as cannabis containing no more than 0.3% delta-9 THC by dry weight—from the Controlled Substances Act schedule, allowing legal cultivation Strong evidence[2]. However, the statute explicitly preserved FDA authority over hemp-derived products. In practical terms: hemp can be grown legally, but adding hemp-derived CBD to a food or supplement for sale in interstate commerce remains governed by the FD&C Act, not the Farm Bill.
Approved Cannabinoid Drugs
Epidiolex (cannabidiol) is the only FDA-approved drug containing a cannabis plant-derived cannabinoid. Approved in June 2018, it is indicated for Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex-associated seizures Strong evidence[3].
Three synthetic cannabinoid drugs are also FDA-approved:
- Marinol (dronabinol, synthetic THC) — approved 1985 for chemotherapy-induced nausea and anorexia associated with AIDS
- Syndros (dronabinol oral solution) — approved 2016 for the same indications
- Cesamet (nabilone, a synthetic THC analog) — approved 1985 for chemotherapy-induced nausea Strong evidence[1]
No whole-plant cannabis product is FDA-approved. State medical cannabis programs operate under state law only and are not recognized as FDA-regulated medicines.
CBD in Foods, Supplements, and Cosmetics
The FDA has maintained a consistent position since 2018 regarding CBD in over-the-counter products:
Dietary supplements: CBD cannot be sold as a dietary supplement Strong evidence[4]. Under the FD&C Act's 'drug exclusion rule' (21 U.S.C. §321(ff)(3)(B)), once a substance is approved as a drug or has been the subject of substantial clinical investigation as a drug, it cannot be marketed as a dietary supplement. CBD meets both criteria.
Food products: CBD cannot be added to human or animal food sold in interstate commerce for the same reason Strong evidence[4].
Cosmetics: Cosmetics containing CBD occupy a less clearly defined position. Cosmetics do not require pre-market FDA approval, but any product making therapeutic or health claims becomes an unapproved drug Strong evidence[1].
In January 2023, the FDA announced that existing regulatory frameworks are inadequate for CBD and asked Congress to develop a new pathway Strong evidence[5]. As of October 2026, Congress has not enacted such a framework. The FDA denied three citizen petitions seeking to allow CBD as a supplement.
The agency has enforced this policy through warning letters sent to companies making explicit disease claims (cancer, Alzheimer's, COVID-19, opioid withdrawal) or marketing CBD to children or pets Strong evidence[6].
Delta-8 THC and Intoxicating Hemp-Derived Cannabinoids
The 2018 Farm Bill defined hemp solely by delta-9 THC content (≤0.3% dry weight). This created a regulatory gap: cannabinoids such as delta-8 THC, delta-10 THC, THC-O, HHC, and high-dose hemp-derived delta-9 products (sold in quantities where individual doses remain under 0.3% delta-9) are available nationally outside any cannabis regulatory system.
The FDA has issued warning letters regarding delta-8 products, particularly those marketed in child-appealing packaging, and has highlighted poison-control reports of adverse events Strong evidence[7]. The DEA has stated that synthetically derived delta-8 (most commercial delta-8 is converted from CBD in a laboratory) is a Schedule I controlled substance, but this position is contested in ongoing litigation Disputed. State regulatory responses vary widely.
These products exist in a legal zone where FDA oversight and testing are minimal, and labeling verification and quality control are absent from federal enforcement.
Enforcement Reality and the Gap Between Law and Practice
FDA enforcement against CBD and intoxicating hemp-derived products has been selective. Typical agency actions include warning letters for egregious disease claims or marketing to vulnerable populations, joint letters with the FTC addressing deceptive advertising, and import alerts on cannabis-containing products Strong evidence[6].
What the FDA has generally not done: systematically remove CBD products from retail shelves, pursue enforcement against mainstream retailers, or verify cannabinoid content accuracy on product labels. Yet independent laboratory studies have repeatedly documented significant label inaccuracies in CBD products Strong evidence[8].
This enforcement gap explains why CBD products are simultaneously prohibited under federal law and widely available in retail channels. An 'FDA-registered facility' label indicates only that the facility submitted paperwork to the FDA—it does not signify FDA approval, inspection, or endorsement of the product. Only Epidiolex carries genuine FDA pre-market approval among cannabis-derived products.
Current Policy and Business Implications
For consumers: Labels claiming 'FDA compliance' or 'FDA approval' for CBD products are marketing language. Federal law prohibits CBD as a dietary supplement or food ingredient regardless of state law or product quality.
For businesses: Selling CBD as a supplement or food ingredient is technically prohibited under federal law. The FTC actively enforces against health claims even when the FDA does not pursue parallel enforcement. Companies face liability for deceptive marketing regardless of FDA action.
For policy tracking: Meaningful changes would come from Congress passing a dedicated hemp or CBD regulatory framework (multiple bills have been introduced) or the DEA rescheduling cannabis from Schedule I. In 2023, the Department of Health and Human Services recommended rescheduling cannabis to Schedule III, which would affect research accessibility and federal tax treatment but would not by itself legalize state cannabis markets or make CBD a legal supplement Strong evidence.
Sources
- Government U.S. Food and Drug Administration. 'FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD).' FDA.gov, 2024.
- Government Agriculture Improvement Act of 2018, Pub. L. No. 115-334, §10113 (hemp definition) and §297D(c) (FDA authority).
- Government U.S. Food and Drug Administration. 'FDA Approves First Drug Comprised of an Active Ingredient Derived from Marijuana to Treat Rare, Severe Forms of Epilepsy.' Press release, June 25, 2018.
- Government Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §321(ff)(3)(B) (dietary supplement exclusion) and §331(ll) (prohibited food acts).
- Government U.S. Food and Drug Administration. 'FDA Concludes that Existing Regulatory Frameworks for Foods and Supplements are Not Appropriate for Cannabidiol, Will Work with Congress on a New Way Forward.' Press release, January 26, 2023.
- Government U.S. Food and Drug Administration. 'Warning Letters and Test Results for Cannabidiol-Related Products.' FDA.gov, updated periodically.
- Government U.S. Food and Drug Administration. '5 Things to Know about Delta-8 Tetrahydrocannabinol – Delta-8 THC.' FDA Consumer Update, September 2021 (updated 2022).
- Peer-reviewed Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R. 'Labeling Accuracy of Cannabidiol Extracts Sold Online.' JAMA. 2017;318(17):1708–1709.
How this page was made
Generation history
Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.
Related
- Cannabis and Workers' Compensation — How states disagree on reimbursement, testing, and the federal-law obstacle.
- Federal Employment Drug Testing Rules — Federal workplace drug testing rules, cannabis Schedule I status, and why state legalizati...
- UN Drug Treaties and Cannabis — Three UN treaties control cannabis globally; legalization exists despite treaty language f...